利用TCGA数据库分析胃腺癌组织<i>PLOD</i>3基因表达及其潜在临床应用价值

陈强; 张涛; 汪自然; 吴正升; 杜卫东

doi:10.16462/j.cnki.zhjbkz.2021.10.022

利用TCGA数据库分析胃腺癌组织PLOD3基因表达及其潜在临床应用价值

doi: 10.16462/j.cnki.zhjbkz.2021.10.022

1.
230032 合肥，安徽医科大学病理学教研室
2.
230022 合肥，安徽医科大学第一附属医院病理科
3.
100055 北京，中国医学科学院北京协和医院检验科

基金项目:

国家自然科学基金 81472493

国家自然科学基金 81972472

安徽省转化医学研究院科研基金 2017zhyx37

详细信息

通讯作者:
杜卫东，E-mail：weidong.du@ahmu.edu.cn

中图分类号: R181+2;R446;R34
计量
- 文章访问数: 283
- HTML全文浏览量: 120
- PDF下载量: 43
- 被引次数: 0
出版历程
- 收稿日期: 2020-08-31
- 修回日期: 2021-04-30
- 网络出版日期: 2021-11-17
- 刊出日期: 2021-10-10

Expression and clinical significance of PLOD3 in gastric adenocarcinoma, an analysis from TCGA data bank

1.
Department of Pathology, Anhui Medical University, Hefei 230032, China
2.
Department of Pathology, The First Affiliated Hospital of Anhui Medical University, Hefei 230022, China
3.
Department of Laboratory Medicine, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Beijing 100055, China

Funds:

The National Natural Science Foundation of China 81472493

The National Natural Science Foundation of China 81972472

The Scientific Research Foundation of the Institute for Translational Medicine of Anhui Province 2017zhyx37

More Information

Corresponding author: DU Wei-dong, E-mail: weidong.du@ahmu.edu.cn

摘要

摘要: 目的利用癌症基因组图谱(the cancer genome atlas, TCGA)数据库分析胃腺癌组织中赖氨酸羟化酶3(procollagen-lysine, 2-oxoglutarate 5-dioxygenase, PLOD3)基因表达及其潜在临床价值。方法使用UALCAN数据库(http://ualcan.path.uab.edu/)分析TCGA中PLOD3基因在胃腺癌及癌旁组织间表达差异；利用Kaplan-Meier模型分析PLOD3基因表达与胃腺癌患者预后相关性；利用LinkedOmics数据库筛查PLOD3相关基因；应用免疫组织化学验证胃腺癌与癌旁正常胃黏膜组织PLOD3来源与分布差异。结果数据库资料表明，胃腺癌组织PLOD3基因表达高于正常胃组织(P＜0.001)；伴有p53基因突变的胃腺癌患者PLOD3基因表达高于无p53基因突变患者(P＜0.001)；PLOD3基因表达与胃腺癌患者生存期相关(HR=1.360，95% CI：1.150~1.610，P < 0.001)；PLOD3基因表达与AP1S1、LRWD1和SLC12A9等基因表达呈正相关(均有P＜0.001)，与CGGBP1、ZNF561和MIER1等基因表达呈负相关(均有P＜0.001)；免疫组化染色结果进一步证实胃腺癌组织PLOD3蛋白表达高于癌旁正常胃黏膜组织(P=0.031)。结论 PLOD3可能成为评价胃腺癌预后以及胃腺癌靶向治疗的有效新靶点。
- PLOD3 /
- 基因表达 /
- 胃腺癌 /
- 数据库
Abstract: Objective To analyze the expression of procollagen-lysine, 2-oxoglutarate 5-dioxygenase (PLOD3) and its clinical significance in gastric adenocarcinoma by means of the cancer genome atlas (TCGA) database. Methods The UALCAN database (http://ualcan.path.uab.edu/) was used to analyze differentiated expression of PLOD3 gene in gastric adenocarcinoma tissues and normal gastric tissues in TCGA database. Kaplan-Meier model was designed to analyze the correlation between the prognosis of patients with gastric adenocarcinoma and the expression of PLOD3. LinkedOmics database was implemented to analyze the genes related to PLOD3. Immunohistochemistry was carried out to verify the expression difference of PLOD3 in gastric adenocarcinoma and adjacent normal gastric tissues. Results The database analysis revealed that the expression level of PLOD3 gene in gastric cancer tissues was higher than that in normal gastric tissues (P < 0.001). Expression of PLOD3 gene in gastric adenocarcinoma with p53 mutation was higher than the cases without p53 mutation (P < 0.001). PLOD3 gene expression was significantly correlated with the survival of patients with gastric adenocarcinoma (HR=1.360, 95% CI: 1.150-1.610, P < 0.001). PLOD3 expression was positively correlated with the genes, such as AP1S1, LRWD1, and SLC12A9 (all P < 0.001), and negatively correlated with the genes, such as CGGBP1, ZNF561 and MIER1 (all P < 0.001). The immunohistochemical observation further demonstrated that more PLOD3 protein was expressed in gastric adenocarcinoma tissues than the adjacent noncancerous gastric tissues (P=0.031). Conclusion PLOD3 would become a valuable biomarker for evaluating the prognosis and targeted therapy for patients with gastric adenocarcinoma.
- PLOD3 /
- Gene expression /
- Gastric adenocarcinoma /
- Database

HTML全文

图 1 PLOD3基因表达与p53基因突变状态和胃癌患者临床分期的关系

Figure 1. Relationship between PLOD3 gene expression and p53 mutation status and clinical stage in patients with gastric adenocarcinoma

下载: 全尺寸图片幻灯片

图 2 PLOD3基因表达与胃腺癌患者预后相关性

Figure 2. The correlation between the expression of PLOD3 gene and the prognosis of patients with gastric adenocarcinoma

下载: 全尺寸图片幻灯片

图 3 PLOD3相关基因分析

Figure 3. Analysis of PLOD3 related genes

下载: 全尺寸图片幻灯片

图 4 PLOD3蛋白在癌旁正常胃组织和胃腺癌组织内的表达

Figure 4. PLOD3 protein expression in normal gastric tissues and gastric adenocarcinoma tissues

下载: 全尺寸图片幻灯片

参考文献(12)

[1]	Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries [J]. CA Cancer J Clin, 2021, 71(3): 209-249. DOI: 10.3322/caac.21660.
[2]	Guo J, Yu W, Su H, et al. Genomic landscape of gastric cancer: molecular classification and potential targets [J]. Sci China Life Sci, 2017, 60(2): 126-137. DOI: 10.1007/s11427-016-0034-1.
[3]	Oki E, Zhao Y, Yoshida R, et al. The difference in p53 mutations between cancers of the upper and lower gastrointestinal tract [J]. Digestion, 2009, 79(Suppl 1): 33-39. DOI: 10.1159/000167864.
[4]	Qi YF, Xu R. Roles of PLODs in collagen synthesis and cancer progression [J]. Front Cell Dev Biol, 2018, 6: 66. DOI: 10.3389/fcell.2018.00066.
[5]	Nicastri A, Gaspari M, Sacco R, et al. N-glycoprotein analysis discovers new up-regulated glycoproteins in colorectal cancer tissue [J]. J Proteome Res, 2014, 13(11): 4932-4941. DOI: 10.1021/pr500647y.
[6]	Shen QY, Eun JW, Lee K, et al. Barrier to autointegration factor 1, procollagen-lysine, 2-oxoglutarate 5-dioxygenase 3, and splicing factor 3b subunit 4 as early-stage cancer decision markers and drivers of hepatocellular carcinoma [J]. Hepatology, 2018, 67(4): 1360-1377. DOI: 10.1002/hep.29606.
[7]	Baek JH, Yun HS, Kwon GT, et al. PLOD3 promotes lung metastasis via regulation of STAT3 [J]. Cell Death Dis, 2018, 9(12): 1138. DOI: 10.1038/s41419-018-1186-5.
[8]	Tsai CK, Huang LC, Tsai WC, et al. Overexpression of PLOD3 promotes tumor progression and poor prognosis in gliomas [J]. Oncotarget, 2018, 9(21): 15705-15720. DOI: 10.18632/oncotarget.24594.
[9]	Wang B, Xu LY, Ge YG, et al. PLOD3 is upregulated in gastric cancer and correlated with clinicopathologic characteristics [J]. Clin Lab, 2019, 65(1): 25-30. DOI: 10.7754/Clin.Lab.2018.180541.
[10]	张显萍, 李莹, 袁才佳, 等. 基于TCGA数据初步筛选胃癌预后相关基因[J]. 临床检验杂志, 2019, 37(5): 396-400. DOI: 10.13602/j.cnki.jcls.2019.05.18. Zhang XP, Li Y, Yuan CJ, et al. Preliminary screening of prognosis-related genes in gastric cancer based on TCGA database [J]. Chin J Clin Lab Sci, 2019, 37(5): 396-400. DOI: 10.13602/j.cnki.jcls.2019.05.18.
[11]	王杨燕, 汪自然, 马筱玲. 基于TCGA数据库分析ALAS1在肝癌中的表达及临床意义[J]. 临床检验杂志, 2020, 38(3): 230-234. DOI: 10.13602/j.cnki.jcls.2020.03.18. Wang YY, Wang ZR, Ma XL. Analysis of the expression and clinical significance of ALAS1 in liver cancer based on TCGA database [J]. Chin J Clin Lab Sci, 2020, 38(3): 230-234. DOI: 10.13602/j.cnki.jcls.2020.03.18.
[12]	Xie D, Li J, Wei S, et al. Knockdown of PLOD3 suppresses the malignant progression of renal cell carcinoma via reducing TWIST1 expression [J]. Mol Cell Probes, 2020, 53: 101608. DOI: 10.1016/j.mcp.2020.101608.